Cash Conversion

Cash Conversion

Zoetis converts reported profit into cash at a high, durable rate. Over the past decade operating cash flow ran about 1.12 times net income, and free cash flow absorbed roughly 86 cents of every dollar of profit after funding a capacity build-out. The conversion is genuine — the earnings lean on little stock compensation and little intangible amortization — but lumpy, swinging with a large and growing inventory book. Free cash flow was $2.28 billion in 2025 [1].

For an investor who has watched the multiple fall by two-thirds, this chapter tests whether the ~28% net margin is spendable cash or accounting profit. It weighs the income statement against the cash-flow statement and finds the profit is largely real cash — the source of downside protection even if growth stays slow — with two honest qualifications: the conversion is uneven year to year, and in 2025 the company distributed more than it earned in cash by leaning on new debt.

Source: derived from the Consolidated Statements of Cash Flows and Statements of Income, FY2016–FY2025 10-Ks [2].

The decade record

The clean way to judge earnings quality is to place three lines side by side: net income, the operating cash flow it generated, and the free cash flow left after capital spending. When operating cash flow tracks or exceeds net income year after year, the profit is cash-backed rather than an accrual.

Source: Consolidated Statements of Cash Flows and Statements of Income, FY2016–FY2025 10-Ks; FY2025 figures [3].

Operating cash flow has exceeded net income in eight of the last ten years, and cumulatively over the decade it ran to about $20.1 billion against $17.9 billion of reported net income — a conversion of roughly 1.12 times [4]. Free cash flow — after the capacity investment discussed below — cumulated to about $15.3 billion, or 86 cents per dollar of reported profit. In 2025 specifically, operating cash flow of $2,904 million covered net income of $2,673 million 1.09 times, and free cash flow reached $2,283 million after $621 million of capital expenditure [5].

Source: derived from Consolidated Statements of Cash Flows and Statements of Income, FY2016–FY2025 10-Ks [6].

The free-cash-flow line is the noisier of the two, dipping to 0.63 times net income in 2022 and 0.69 times in 2023 before recovering above 0.85 times. That dispersion is the real texture of this business: the profit becomes cash reliably, but the timing of when it becomes cash depends on the inventory and capital cycles below.

Why the profit is cash

Two features separate Zoetis from the many pharmaceutical companies whose reported earnings need heavy adjustment before they resemble cash. First, the non-cash charges that flatter cash flow at acquisitive drugmakers are small here. Depreciation and amortization was $487 million in 2025, of which amortization of acquired intangibles was only $128 million — about 1.4% of revenue [7]. Share-based compensation was $83 million, roughly 3% of net income [8]. A business that generates cash flow by adding back large intangible amortization and paying employees in stock is converting less than it appears; Zoetis does little of either.

Second, the gap between statutory and management-preferred earnings is narrow. Adjusted net income — the company's non-GAAP figure, which strips purchase-accounting and acquisition items — was $2,847 million in 2025 against reported net income of $2,673 million, a difference of about 6.5% [9]. The same gap was 8.3% in 2024 and 4.8% in 2023 [10]. A single-digit adjustment is unusual in this sector, where "adjusted" earnings routinely run tens of percent above the audited number. Here, the audited number and management's number are close, and both are close to cash.

Source: FY2025 10-K — performance summary [11] and Consolidated Statements of Cash Flows [12].

Where the lumpiness comes from

The conversion is real; the timing is not smooth. Two lines explain almost all of the year-to-year swing.

The first is capital spending. Capital expenditure climbed from about 6% of revenue in 2021 to a peak of 8.6% in 2023 — $732 million — as Zoetis expanded manufacturing, then eased back to $621 million, or 6.6% of revenue, in 2025 [13]. Capital expenditure has run above depreciation for years — $621 million against $487 million of D&A in 2025 — which means reported free cash flow is struck after growth investment, not merely maintenance. As the build-out normalizes, the capex-to-D&A gap should narrow and free cash flow should track closer to operating cash flow.

The second, larger swing factor is inventory. Zoetis carried $2,464 million of inventory at the end of 2025, up from $1,923 million in 2021 — roughly 337 days of cost of sales, and rising [14]. Management attributes the build to production "for the forecasted demand of certain products" [15]. Inventory alone consumed $199 million of cash in 2025 and $361 million in 2023; combined with a $236 million receivables build, working capital was the main reason operating cash flow slipped slightly year on year even as net income rose [16].

Source: Consolidated Balance Sheets, FY2021–FY2025 10-Ks; days derived from reported cost of sales [17].

What a slowdown does to the cash

The demand softness examined in Demand Diagnosis makes the inventory book cut both ways, and the direction matters for a margin-of-safety reader.

On the downside, a large stock of product built for "forecasted demand" that has since weakened is exposed to write-downs. Zoetis already runs a recurring inventory-provision charge — $68 million in 2025, $97 million in 2024 and $115 million in 2023 — so obsolescence is a live cost, not a hypothetical [18]. A sharper demand shortfall would raise it.

On the other side, working capital is a cash reservoir in a downturn. If Zoetis stops building inventory and lets 337 days of stock run down, the unwind releases cash into operating cash flow — the mechanical counterpart of the distributor and retail destocking that pressured Q1 2026 revenue. In other words, the same slowdown that dents the income statement tends to support the cash-flow statement for a period. This is why high-margin, self-funding businesses often show their steadiest free cash flow precisely when growth disappoints, and it is the core of the downside protection here: the business threw off $2.28 billion of free cash flow in a year its US companion-animal engine stalled.

Interest is the one structural drag that only moves one way. Net interest expense was $222 million in 2025, little changed from $225 million in 2024 despite a step-up in gross debt, because the newly issued convertible carries a low coupon [19]. Against operating income of roughly $3.6 billion, interest is covered about 16 times, and net debt sits near 1.6 times EBITDA — comfortably inside the range that would trouble the reader's never-touch-bankruptcy line [20]. The solvency question is addressed in full elsewhere; for cash conversion, the point is narrow — rising debt trims free cash flow at the margin but does not threaten its generation.

The 2025 caveat

Strong conversion is not the same as living within cash flow. In 2025 Zoetis returned $3,235 million to shareholders through buybacks and $889 million in dividends — $4.12 billion against $2.28 billion of free cash flow, or about 1.8 times what the business generated [21]. The gap was bridged with debt: $2,000 million of convertible notes and $1,848 million of senior notes, against $1,350 million of repayments [22]. That is a capital-allocation choice, not a cash-conversion flaw, and it belongs to the governance and balance-sheet question the report takes up next. Noted here only so the free-cash-flow strength is not mistaken for self-restraint: the cash is real, but in 2025 the company chose to distribute more than it made.

The read

On the evidence, cash conversion is a genuine strength and a source of downside protection in the case. A decade of operating cash flow above net income, a single-digit non-GAAP gap, minimal stock compensation and light intangible amortization all point the same way: the reported ~28% net margin is spendable cash, and the business self-funds through a demand slowdown.

The strongest fact against reading this as pristine is the inventory book — $2.46 billion and 337 days, built for a demand forecast that has since softened, carrying a live write-down cost. It makes free cash flow lumpy and exposes it to obsolescence if the slowdown deepens. What would change the read: a sustained rise in the inventory-provision charge, or receivables and inventory growing faster than sales for several quarters, would signal the conversion is decaying rather than merely cycling. Through 2025, the evidence runs the other way — the cash keeps arriving.